Invest in the Future of Spinal Discs

  • Over 800,000 people need disc replacements every year
  • Our diamond composite implants last a lifetime
  • 500+ patients treated
  • 83 patents protect our innovations
  • Our FDA clinical studies are being led by a legendary spinal surgeon

$5.75 Share Price

Why Current Spinal Treatments Fail

Spinal fusions limit mobility and can weaken discs. That’s why replacement discs are becoming more popular, but these can wear out, leaving debris in patients’ bodies.

A Superior Solution

Our implants are made out of our patented polycrystalline diamond composite, so they will never wear out. And our patented tri-lobe design mimics the natural motion of a healthy spine, creating better stability.

Polycrystalline Diamond

Our patented polycrystalline diamond material is almost entirely composed of carbon, in it’s strongest-material-in-the-universe form. It will last beyond a patient’s lifetime and creates no detectable wear debris.5

Tri-Lobe Design

Our patented Tri-Lobe design seats three spherical lobes within three pockets. The design mimics the natural motion of a healthy spine and creates better stability.7

We Have 83 Patents and 500+ Successful Patients Already

We’ve earned 83 patents for our replacement disc and 500+ patients overseas are successfully using our diamond-hardened implants already. Now we’re turning our sights on our home market in the US.

A Better Replacement Disc Could Be Worth $1 Billion

Degenerative disc disease is the second most common reason to visit the doctor behind the common cold. And artificial cervical discs are the fastest-growing segment of the spine market. A functional, lasting solution to this problem has massive market potential.

$1B1

Global Cervical Implant Market

800,0001

Cervical Implant Procedures Per Year Globally

85%2

Degenerative Disc Disease Affects 85% of People By Age 50

We’ve Helped 500+ Patients Already

We’ve already implanted our man-made diamond discs in over 500 patients outside the US. With all the benefits we offer, it’s easy to see why patients are turning to our solution. Once we get FDA approval we plan to hit the ground running in the US market. 

Long-Lasting

Last for full lifetime of patient.5

Natural Kinematics

Mimics the natural motion of a healthy spine and creates better stability‍7

Cost-Effective

~$6,000 cheaper for the patient.3

Faster Recovery

Patients can return to work 38 days sooner.3

Long-Lasting

Last for full lifetime of patient

Natural Kinematics

Mimics the natural motion of a healthy spine and creates better stability.

Cost-Effective

~$6,000 cheaper for the patient

Faster Recovery

Patients can return to work 38 days sooner

Problems with current treatments

Non-Anatomic Motion

Debris From Wear

Fusions Can Weaken Adjacent Discs

We Have a First-Mover Advantage

Only 2 of the 5 largest spine companies market a viable disc replacement. Our first-of-its-kind replacement disc is better because it doesn’t wear out and restores natural mobility. 3 of the 5 companies have no replacement disc at all.

83: Patents

On Pathway to Initiate FDA Clinical Studies

Our Path to FDA Approval

Our next step is to start FDA clinical studies. Our clinical trials are being led by legendary spinal surgeon Dr. Richard Guyer. Along with our 500+ successful surgeries overseas, we feel strongly about getting approval.

Our Growth Potential

Artificial cervical discs are the fastest growing segment of the spine market (18% CAGR
2022-2028).4

Our Advantage

Only 2 of the 5 largest spine companies currently market a viable disc replacement. The others must acquire a cervical disc replacement device to remain competitive.

ALAN S. LAYTON

Chairman of the Board and CEO

In addition to his leadership at Dymicron, Mr. Layton has had an impressive career in real estate, construction, industrial engineering, and software development. He served as the Chairman of the Salt Lake Area Chamber of Commerce, a member of the Organizing Committee for the 2002 Olympic Games, and other community boards and activities. He earned a BS in Civil Engineering from Brigham Young University.

JEFF BENNETT

President and Chief Operating Officer

Jeff Bennett is a medical device professional with expertise in product development, manufacturing, quality assurance, and regulatory affairs, as well as senior management. Before joining Dymicron, he oversaw a 100 percent increase in revenue during his two-and-a-half-year tenure as General Manager of Merit Medical’s Richmond Division. He has contributed to the development and commercialization of a variety of new medical device products that range from left-ventricular assist devices to in-vitro diagnostics. Jeff graduated from the University of Utah with a degree in Chemistry.

TED BIRD

Executive Vice President, Corporate Development and Chief Strategy Officer

Ted Bird has over 35 years of global commercial experience in the medical device arena, including 30 years in the spine industry specifically. He led global marketing, medical education, and business development at Medtronic Sofamor Danek, and served as VP of Spine Arthroplasty Education at Depuy Spine/Johnson & Johnson, President of Orthofix Spinal Implants Division, and Non-Executive Chairman of the Board at Apifix. Additionally, he served as Chief Commercial Officer at Titan Spine and founded Bird Medical Group, a strategic consulting firm. Ted graduated from Brown University with a bachelor’s degree in International Relations.

GUNTHER PEETERS

Senior Vice President of Commercial Operations

Gunther Peeters has 15 years of experience with innovative game-changing spinal technologies. He played a critical role in the expansion and clinical use of both the M6 discs driving market leadership status for Spinal Kinetics, prior to joining German R&D company Orthobion, GmbH as Director of Business Development. He subsequently served as Vice President of the European business for Vexim and later served as Vice President, International Market Development for Mainstay Medical.

ERIC LANGE

Vice President,
Research and Development

Mr. Lange joined Dymicron in May 2019 to spearhead the company’s efforts to gain US approval for the Triadyme®-C Cervical Disc. Eric has over 27 years of experience in the spinal device industry including 20 years in product development leadership positions at Medtronic where he was a Technical Fellow, two-time Quest Award winner, and Technical Contributor of the Year. Eric has over 100 issued patents and 29 worldwide product launches. He earned his Master’s degree in Biomechanics and a Bachelor’s degree in Aerospace Engineering from the University of Cincinnati.

DAVID HARDING, PhD.

Principal Engineer

David Harding is a spine scientist focused on the emulation of natural spinal motion with total disc arthroplasty and a biomedical engineer focused on elegant, effective implantation systems. He has 12 years working in the orthopedic implant industry designing implants with Polycrystalline Diamond bearing surfaces and the instrument systems to implant them. He was trained as a materials scientist with a focus first in metallurgy and later in polycrystalline diamond. David has a Bachelor’s degree in Metallurgical Engineering and a PhD. in Materials Science from the University of Utah.

FAQs

What’s your share price?

$5.75

What is the minimum investment size?

The minimum investment size for this current round is $1,000.50

What kind of shares are you issuing?

Common

Why Should I Invest?

Only 2 of the 5 largest spine companies currently market a viable disc replacement. The others must acquire a cervical disc replacement device to remain competitive. We solved the biggest problem in the $1 billion1 cervical implant market. Our man-made diamond artificial discs restore the full range of motion for patients and will never wear out.5

How Do I Know People Will Buy This Solution?

Degenerative Disc Disease causes everything from neck and arm pain to disability in 3 million people each year6

What’s Next for Dymicron?

Our next step is winning FDA clearance to market our solution in the US. Between our patent protections and FDA clearance, we believe we can address 80% of the relevant market.

Why Didn't A Bigger Company Do This Already?

Only 2 of the 5 largest spine companies currently market a viable disc replacement. The others must acquire a cervical disc replacement device to remain competitive.

How do I get a return on my investment?

Since we are still in the funding round there is currently no market for liquidity for the shares sold. You should plan to hold your investment for a significant period before a liquidation event occurs.

What industries are you currently focused on?

We solved the biggest problem in the $1 billion1 cervical implant market. Our man-made diamond artificial discs restore the a more natural, kinematic of motion for patients and will never wear out.5

Do you plan to expand internationally?

We are already working internationally. We’ve implanted over 500 of our patented cervical discs in patients in Europe. We are expanding internationally in select markets, while remaining focused on obtaining FDA clearance in the US.

How many patents do you have?

83 patents across design and manufacturing

What are your advantages against competitors?

Disc replacements are an increasingly popular treatment over spinal fusion procedures. But all of the legacy disc replacements have the potential to fail because the metal and plastic components wear out over time, leaving debris in the body. Dymicron’s patented cervical total disc replacement Triadyme®-C, is restoring people’s lives. Its man-made diamond articulating surface design means it is very unlikely to wear out over time like current artificial discs, and it’s Tri-Lobe design restores a more natural, kinematic range of motion in patients.

Join The Discussion

Loading Comments

$5.75

Price per Share

INVEST NOW

Keep in Touch

Join Dymicron's mailing list to receive live investor updates!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Sign-up for our investor brief

Submission received! Check your inbox for the Dymicron updates.